We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Danaher Gears Up to Post Q3 Earnings: What Lies Ahead for the Stock?
Read MoreHide Full Article
Key Takeaways
Danaher is expected to report Q3 revenues of $26.3 billion, up 8.2% year over year.
Biotechnology, Diagnostics and Life Sciences growth, plus Masimo, may boost quarterly sales.
Rising input costs, product mix changes and currency headwinds may pressure Danaher's profits.
Danaher Corporation (DHR - Free Report) is scheduled to release third-quarter 2026 results on Oct. 21, before market open.
The Zacks Consensus Estimate for revenues is pegged at $26.3 billion, which indicates an increase of 8.2% from the year-ago quarter’s figure. The consensus mark for earnings is pinned at $1.94 per share, which has remained steady in the past 30 days. The estimate indicates an increase of 1.6% from the figure reported in the year-ago quarter. The company’s bottom line surpassed the Zacks Consensus Estimate in each of the preceding four quarters, the average beat being 5.7%.
Let’s see how things have shaped up for Danaher this earnings season.
Key Factors and Estimates for Q3
Strength in the bioprocessing business, driven by an increase in demand from large pharmaceutical and biopharma customers, is expected to have aided the Biotechnology segment. The segment’s performance is also likely to have benefited from solid demand for equipment and consumables. For the third quarter, the Zacks Consensus Estimate for the segment’s total sales is pegged at $1.87 billion, indicating a 3.9% rise from the year-ago reported number.
Stabilizing pricing and improving volumes, as procurement and reimbursement effects have begun to moderate, are expected to drive the Diagnostics segment’s results. For the third quarter, the Zacks Consensus Estimate for the segment’s total sales is pegged at $2.83 billion, indicating a 15% rise from the year-ago reported number.
Increase in demand across filtration, instruments and consumables businesses is likely to have boosted the performance of the Life Sciences segment in the quarter. For the third quarter, the Zacks Consensus Estimate for the segment’s total sales is pegged at $1.84 billion, indicating a 2.8% rise from the year-ago reported number.
Danaher acquired Masimo in June 2026, which expanded the Diagnostics segment by adding sensor technology and AI-enabled monitoring. This is expected to have augmented the company’s top line in the third quarter.
However, the escalating costs and operating expenses, due to increasing input costs and product mix changes, are likely to have weighed on DHR’s bottom line in the to-be-reported quarter.
The company has considerable exposure to overseas markets. Given its substantial international operations, foreign currency headwinds are likely to have marred its profitability.
Our proven model predicts an earnings beat for DHR this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat, which is not the case here, as elaborated below.
Earnings ESP: DHR has an Earnings ESP of +0.30% as the Most Accurate Estimate is pegged at $1.93 per share, which is higher than the Zacks Consensus Estimate of $1.92. You can uncover the best stocks before they’re reported with our Earnings ESP Filter.
Here are some other companies within the broader Medical sector, which according to our model, have the right combination of elements to beat on earnings in this reporting cycle.
Acadia Healthcare Company, Inc. (ACHC - Free Report) has an Earnings ESP of +4.84% and a Zacks Rank of 3 at present. The company is slated to release third-quarter 2025 results on Nov. 4.
Acadia Healthcare’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 47%.
Agios Pharmaceuticals, Inc. (AGIO - Free Report) has an Earnings ESP of +9.37% and a Zacks Rank of 3 at present. The company is scheduled to release third-quarter 2026 results on Nov. 5.
Agios Pharmaceuticals’ earnings surpassed the Zacks Consensus Estimate in each of the preceding four quarters, the average surprise being 7.4%.
CVS Health Corporation (CVS - Free Report) has an Earnings ESP of +0.79% and a Zacks Rank of 3 at present. The company is slated to release third-quarter 2026 results on Nov. 4.
CVS Health’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 20.5%.
View the Zacks #1 Rank List
Image: Bigstock
Danaher Gears Up to Post Q3 Earnings: What Lies Ahead for the Stock?
Key Takeaways
Danaher Corporation (DHR - Free Report) is scheduled to release third-quarter 2026 results on Oct. 21, before market open.
The Zacks Consensus Estimate for revenues is pegged at $26.3 billion, which indicates an increase of 8.2% from the year-ago quarter’s figure. The consensus mark for earnings is pinned at $1.94 per share, which has remained steady in the past 30 days. The estimate indicates an increase of 1.6% from the figure reported in the year-ago quarter. The company’s bottom line surpassed the Zacks Consensus Estimate in each of the preceding four quarters, the average beat being 5.7%.
Let’s see how things have shaped up for Danaher this earnings season.
Key Factors and Estimates for Q3
Strength in the bioprocessing business, driven by an increase in demand from large pharmaceutical and biopharma customers, is expected to have aided the Biotechnology segment. The segment’s performance is also likely to have benefited from solid demand for equipment and consumables. For the third quarter, the Zacks Consensus Estimate for the segment’s total sales is pegged at $1.87 billion, indicating a 3.9% rise from the year-ago reported number.
Stabilizing pricing and improving volumes, as procurement and reimbursement effects have begun to moderate, are expected to drive the Diagnostics segment’s results. For the third quarter, the Zacks Consensus Estimate for the segment’s total sales is pegged at $2.83 billion, indicating a 15% rise from the year-ago reported number.
Increase in demand across filtration, instruments and consumables businesses is likely to have boosted the performance of the Life Sciences segment in the quarter. For the third quarter, the Zacks Consensus Estimate for the segment’s total sales is pegged at $1.84 billion, indicating a 2.8% rise from the year-ago reported number.
Danaher acquired Masimo in June 2026, which expanded the Diagnostics segment by adding sensor technology and AI-enabled monitoring. This is expected to have augmented the company’s top line in the third quarter.
However, the escalating costs and operating expenses, due to increasing input costs and product mix changes, are likely to have weighed on DHR’s bottom line in the to-be-reported quarter.
The company has considerable exposure to overseas markets. Given its substantial international operations, foreign currency headwinds are likely to have marred its profitability.
Danaher Corporation Price and EPS Surprise
Danaher Corporation price-eps-surprise | Danaher Corporation Quote
Earnings Whispers
Our proven model predicts an earnings beat for DHR this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat, which is not the case here, as elaborated below.
Earnings ESP: DHR has an Earnings ESP of +0.30% as the Most Accurate Estimate is pegged at $1.93 per share, which is higher than the Zacks Consensus Estimate of $1.92. You can uncover the best stocks before they’re reported with our Earnings ESP Filter.
Zacks Rank: DHR currently carries a Zacks Rank of 2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Other Stocks to Consider
Here are some other companies within the broader Medical sector, which according to our model, have the right combination of elements to beat on earnings in this reporting cycle.
Acadia Healthcare Company, Inc. (ACHC - Free Report) has an Earnings ESP of +4.84% and a Zacks Rank of 3 at present. The company is slated to release third-quarter 2025 results on Nov. 4.
Acadia Healthcare’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 47%.
Agios Pharmaceuticals, Inc. (AGIO - Free Report) has an Earnings ESP of +9.37% and a Zacks Rank of 3 at present. The company is scheduled to release third-quarter 2026 results on Nov. 5.
Agios Pharmaceuticals’ earnings surpassed the Zacks Consensus Estimate in each of the preceding four quarters, the average surprise being 7.4%.
CVS Health Corporation (CVS - Free Report) has an Earnings ESP of +0.79% and a Zacks Rank of 3 at present. The company is slated to release third-quarter 2026 results on Nov. 4.
CVS Health’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 20.5%.